Abstract |
High serum uric acid level (SUA) and chronic kidney disease (CKD) are risk factors for cardiovascular events (CVEs). However, their interactions as cardiovascular risk factors remain unknown. This subanalysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study included 7629 patients, in whom the serum creatinine level was measured at least twice. The study examined the impact of hyperuricemia (SUA ≥7 mg dl(-1)) on CVE according to the level of renal dysfunction and whether early changes in SUA predicted future glomerular filtration rates (GFRs). The mean follow-up period was 3.1 years. The patients were divided into three groups according to the baseline estimated GFR (eGFR): groups A, B and C with eGFR <45, 45-59 and ≥60 ml min(-1) per 1.73 m(2), respectively. eGFR increased from 38.1 to 57.6, from 52.8 to 67.5 and from 74.7 to 80.7 ml min(-1) per 1.73 m(2) in groups A, B and C, respectively. In non-hyperuricemic patients, the CVE rate was 10.83, 4.98 and 4.21/1000 person-years in groups A, B and C, respectively, while in hyperuricemic patients, the corresponding values were 14.18, 17.02 and 5.93. Thus, hyperuricemia increased the risk of CVE only in group B (relative risk (RR) 3.43 (95% confidence interval (CI) 1.55 to 7.60); P<0.002). The final change in the eGFR was negatively correlated with the change in SUA from baseline to year 1 (P<0.001). CVEs were more frequent in those with a decrease in eGFR. Hyperuricemia may be a major determinant of increased cardiovascular risk in CKD stage 3A, and SUA may be involved in the progression of CKD. Changes in the GFR influence the rate of CVE.
|
Authors | Sadayoshi Ito, Hiroaki Naritomi, Toshio Ogihara, Kazuyuki Shimada, Kazuaki Shimamoto, Heizo Tanaka, Nobuo Yoshiike |
Journal | Hypertension research : official journal of the Japanese Society of Hypertension
(Hypertens Res)
Vol. 35
Issue 8
Pg. 867-73
(Aug 2012)
ISSN: 1348-4214 [Electronic] England |
PMID | 22573200
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Antihypertensive Agents
- Uric Acid
- Losartan
|
Topics |
- Aged
- Angiotensin II Type 1 Receptor Blockers
(adverse effects, therapeutic use)
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Blood Pressure
(drug effects)
- Cardiovascular System
(drug effects)
- Female
- Glomerular Filtration Rate
(drug effects)
- Humans
- Hypertension
(drug therapy, physiopathology)
- Kidney
(drug effects)
- Kidney Function Tests
- Linear Models
- Losartan
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Proteinuria
(metabolism)
- Uric Acid
(blood)
|